Minan Peter Francis purchased $49K of USPH

Minan Peter Francis purchased 780 shares of U S PHYSICAL THERAPY INC /NV (USPH) at an average of $62.53 ($61.50–$63.14) across 2 trades over 2026-06-08 to 2026-06-09.

Original reporting
SEC EDGAR · Minan Peter Francis
Published Jun 10, 2026, 10:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 10:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$USPH
Bullish
low confidence
Mentioned
$USPH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$USPHBullishLow
01

Why it matters

Traders may treat the buy as a small sentiment input, but without new guidance, contracts, or regulatory developments, it is unlikely to drive a sustained repricing.

02

Market read

New insider-buy disclosure (director open-market purchase) with modest size; useful for sentiment/flow checks rather than a standalone catalyst.

03

What to watch

The article provides only the transaction details (size, price range, post-holdings) without context on prior holdings, compensation timing, or whether other insiders acted.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10 for trades dated 2026-06-08 to 2026-06-09

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for U S Physical Therapy Inc /NV (USPH).

Company-level read

Ticker impact

$USPHBullishLow confidence
Context

SEC Form 4 shows director Minan Peter Francis bought 780 shares of U S Physical Therapy (USPH) in open-market trades for ~$48.8K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

The filing is a routine insider buy with relatively small dollar value and no accompanying operational/regulatory update in the text.

Market effects

No sector-wide read-through; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or routine planned activity; this filing explicitly notes no 10b5-1 plan, but that still doesn’t confirm conviction.

Key entities

  • U S Physical Therapy Inc /NV

    Subject of the Form 4 insider transaction disclosure.

  • Minan Peter Francis

    Director who executed open-market purchases of USPH shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$USPHMedAI 8/10

U.S. Physical Therapy Q3 Earnings Call Highlights

U.S. Physical Therapy (USPH) reported Q3 earnings, with adjusted physical therapy margins rising 60 basis points YoY to 19%, despite higher medical costs. The company plans acquisitions and clinic expansions. Industrial injury prevention revenue grew 14% to $33M. GAAP net income fell to $11M from $13M YoY. USPH ended Q3 with $38M in cash and $247M in borrowings.

$USPHHigh

USPH Reports Third Quarter 2026 Results

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. CONTACT: U.S. Physical Therapy, Inc. Nchacha Etta, Chief Financial Officer email: netta@usph.com (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424 USPH Reports Third Quarter 2026 Results, Record High Visits and Revenue Per Visit Houston, TX, November 4, 2026 – U.S. Phy

$USPHHigh

US Physical Therapy Inc (USPH) (Q3 2026) Earnings Call Highlights: Record Visits

US Physical Therapy Inc (USPH) reported Q3 2026 revenue growth of 13% to $223M, driven by record patient visits and hospital affiliations. Net rate per visit hit $112, and EBITDA grew over 16%. The company reaffirmed full-year EBITDA guidance of $102M-$106M but faced higher self-insured group health costs and increased interest expenses. Management expects continued growth from hospital partnerships and cautious about medical cost trends.